Catalyst Pharmaceutical Partners, Inc. Initiates U.S. Phase II Clinical Trial of CPP-109 in Patients With Cocaine Dependence
Tuesday, July 10, 2007
Catalyst Pharmaceutical Partners, Inc., a specialty pharmaceutical company that acquires or in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, today announced that it has initiated its randomized, double-blind, placebo-controlled U.S. Phase II clinical trial of CPP-109 in patients with cocaine dependence. CPP-109, an orally administered, small molecule drug which inhibits psychostimulant-induced dopamine release, is Catalyst's lead compound, vig